The ability of DMC and OSU to downregulate the expression of these anti-apoptotic proteins (e.g., Mcl-1, Bcl-2) may therefore represent an appealing strategy to re-sensitize cancer cells to chemotherapeutic agents. This evidence concerns the gene MCL1 and cancer.